About AMO-04

AMO Pharma entered into a development and license agreement with Numedicus Limited to advance the development of AMO-4, a glutamate modulator, and related New Chemical Entities for the treatment of Rett syndrome and certain breathing disorders. AMO-04 has shown significant promise as a potential treatment for Rett syndrome based on extensive screening completed by the Scout Program sponsored by Rettsyndrome.org and for certain breathing disorders based on research conducted by Numedicus collaborators.